Predicting Psychiatric Hospital Admission Among Adults With Schizophrenia
Abstract
Objective:
The authors identified patient characteristics that increased risk of hospital admission among adults with schizophrenia.
Methods:
A total of 1,460 participants in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) clinical trial were followed from the time they began a randomized trial of medication to first schizophrenia-related hospital admission.
Results:
In 869 person-years of follow-up, 203 patients were hospitalized. Increased risk of hospital admission was associated with early age (≤17 years) of first antipsychotic treatment (adjusted hazard ratio [AHR]=2.16, 95% confidence interval [CI]=1.49–3.11), psychiatric hospitalization in past year (AHR=2.99, CI=2.23–4.00), having had DSM-IV alcohol (AHR=1.56, CI=1.16–2.10) or drug (AHR=1.50, CI=1.13–2.00) use disorders in the past five years, and baseline severe symptoms according to the Clinical Global Impressions Scale (AHR=1.54, CI=1.04–2.27), presence of tardive dyskinesia (AHR=1.55, CI=1.07–2.23), a high score on the positive symptoms subscale of the Positive and Negative Syndrome Scale (AHR=1.52, CI=1.07–2.15), and low social function (AHR=1.45, CI=1.03–2.04). As compared with olanzapine, the drugs quetiapine (AHR=2.14, CI=1.39–3.31), perphenazine (AHR=1.80, CI=1.11–2.94), and ziprasidone (AHR=2.70, CI=1.64–4.44) were associated with increased hospitalization risk. Risperidone was associated with a lower hospitalization risk than quetiapine (AHR=1.50, CI=1.01–2.22) and ziprasidone (AHR=1.89, CI=1.19–3.01).
Conclusions:
Efforts to lower hospital admission risk among individuals with schizophrenia should focus on history of early onset, recent inpatient admission, severe positive symptoms, poor social function, high global illness severity, and comorbid substance use disorders and on selection of an appropriate antipsychotic medication. (Psychiatric Services 62:1138–1145, 2011)
Inpatient treatment is the most restrictive and costly component of community mental health care (1). Although hospital admission represents only one aspect of outcome, it is a clinically disruptive event that commonly indicates that the patient's symptoms cannot be safely managed outside an institutional setting. Identifying risk factors for psychiatric hospital admission can have clinical and policy implications for patient care, program development, and service planning.
Inpatient admissions frequently occur in the community management of schizophrenia. The risk of psychiatric hospital admission for schizophrenia exceeds that for bipolar disorder, depression, and other psychiatric disorders (2). In the United States there are more than 800,000 hospital admissions each year for treatment of schizophrenia at an aggregate cost exceeding $3 billion (3). The average length of inpatient stays for schizophrenia exceeds that for other major psychiatric disorders (3).
Several factors appear to influence risk of psychiatric hospital admission among individuals with schizophrenia. Risk tends to increase with antipsychotic medication nonadherence (4), poor global functioning (5), and co-occurring substance use disorders (5). Patients with previous psychiatric hospital admissions (5,6) and past suicide attempts (6) are also at high risk of future hospital admission. In addition, younger adults with schizophrenia are at greater risk than older adults (6). Consistent differences in rates of hospital admission for schizophrenia patients, however, have not been shown to be related to patient marital status or gender (7), though men with schizophrenia tend to spend more time in the hospital than women with schizophrenia (8,9).
Little is also known about the role of symptom type or severity in predicting inpatient admission. Depressive symptoms, for example, sometimes (5), but not consistently (10), have been associated with relapse or hospital admission among individuals with schizophrenia. Methodological limitations have constrained progress in clarifying risk factors for hospital admission among individuals with schizophrenia. Much of the research has involved medical claims that lack diagnostic precision and clinical detail. Other methodological limitations include reliance on cross-sectional rather than on prospective designs (11,12), use of diagnostically mixed psychiatric samples (11), and study of comparatively few individuals (10).
This study examined risk of psychiatric hospitalization among individuals who were enrolled in the first phase of the National Institute of Mental Health (NIMH) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) clinical trial. The first phase followed a well-characterized cohort of adults with schizophrenia for up to 18 months or until antipsychotic treatment was discontinued for any reason. According to a previous report, the percentage of CATIE participants who were hospitalized during the first phase significantly varied by medication assignment—olanzapine, 11%, risperidone, 15%, perphenazine, 16%, ziprasidone, 18%, and quetiapine, 20% (13). This report extended this analysis to examine associations of factors related to patients, including sociodemographic characteristics, psychiatric symptoms, psychiatric comorbidity, and treatment history, with risk of psychiatric hospital admission.
Methods
Source of data
Data were drawn from phase 1/1A of the NIMH CATIE study, which compared the effectiveness of antipsychotic medications (13). Adults who were between the ages of 18 and 65 years and who were diagnosed with the Structured Clinical Interview for DSM-IV (14) as meeting criteria for schizophrenia were randomly assigned as outpatients to receive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone under double-blind conditions. Phase 1A included patients with tardive dyskinesia who were otherwise eligible for the study and were randomized to olanzapine, quetiapine, risperidone, or ziprasidone but not to perphenazine. Participants were followed for up to 18 months or until the assigned medication was discontinued. Schizoaffective disorder, mental retardation, or other cognitive disorders, as well as a documented serious adverse reaction or clinical nonresponse to any study medication, were exclusion criteria. Patients in their first episode of schizophrenia, pregnant or breast-feeding women, and patients with serious and unstable medical conditions were also not eligible.
Deidentified data were obtained from the NIMH Limited Access Clinical Trial Data program. This project was determined to be exempt from human subjects review by the New York State Psychiatric Institute Institutional Review Board.
Sociodemographic characteristics
At baseline, a sociodemographic assessment was performed. We classified patients by age in years (18–35, 36–45, and 46–65), sex, race or ethnicity (white, African American, Hispanic, or other), marital status (married, previously married, or never married), highest level of formal education in years (0–11, 12, or >12), current employment status (full- or part-time employment or not employed), and living situation (alone or with others).
Clinical characteristics
Patients were also characterized at baseline by having experienced one or more episodes of inpatient mental health care in the past year, age of first antipsychotic medication use (≤17 or >17 years), and a self-report measure of lifetime intentional physical injury of others (15). On the basis of the SCID (14), patients were assessed for major depressive disorder, alcohol use disorders, drug use disorders, and anxiety disorders during the past five years. The Abnormal Involuntary Movement Scale (AIMS) (16) at baseline classified patients with respect to probable tardive dyskinesia, defined as a moderate (≥3) rating on at least one AIMS item or a mild (≥2) rating on at least two items (17).
Symptom measures
Symptom severity was assessed at baseline with the Positive and Negative Syndrome Scale (PANSS) (18). Low, intermediate, and high severity tertiles were constructed for the PANSS total scale (30 items) and for the positive symptom (seven items), negative symptom (seven items), and general psychopathology (16 items) subscales. Results for clinician-rated Clinical Global Impressions (CGI) Scale at baseline were coded as mild (ratings of 1–3), moderate (rating of 4), or severe (ratings of 5–7). Baseline ratings for the nine-item Calgary Depression Rating Scale were used to assess severity of depressive symptoms as either low (<6) or high (≥6) (19).
Antipsychotic medications
According to medication assignment, patients were classified as receiving treatment with olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone. Ziprasidone was included following its approval by the U.S. Food and Drug Administration during the recruitment period, and patients with current tardive dyskinesia were systematically excluded from assignment to treatment with perphenazine (13).
Health and attitude measures
Social functioning was measured at baseline with the 21-item clinician administered Quality of Life Scale (20). Total scores were classified in low (0–2.2), intermediate (2.3–3.1), and high (>3.1) tertiles. Subjective response and attitude toward antipsychotic medications were assessed with the ten-item Drug Attitude Inventory (21); scores ≤3 were considered favorable and scores >3, unfavorable. The 11-item Insight Into and Awareness of Illness Questionnaire (ITAQ) was scored as either low (≤16) or high (>16). This scale measures awareness that one's various mental health symptoms indicate that the illness is sufficiently serious to require treatment (22). The physical component summary scale of the 12-item Medical Outcomes Study survey (SF-12 PCS) (23) measured whether patients had low (≤51) or high (>51) general physical health status at baseline.
Outcome
The outcome was first hospital admission for exacerbation of schizophrenia following randomization while receiving the initial randomized medication as reported by the treating physicians. In the primary analyses, days at risk for hospital admission were limited to the period from baseline to drug discontinuation. Because use of acute care services increases after an antipsychotic is switched (24), a sensitivity analysis was performed in which hospital admissions within 14 days after medication discontinuation were assigned to the first medication. In an earlier CATIE report (13), hospital admissions were associated with the first medication for up to 30 days following its discontinuation. Another sensitivity analysis used the annual hospitalization risk (the number of hospitalizations divided by total person-years of exposure) as the outcome instead of first hospital admission.
Analytic plan
The frequency of first-observed inpatient admissions for exacerbations of schizophrenia per 10,000 follow-up days on initially randomized antipsychotic medication was determined overall and stratified by baseline patient characteristics. Observations were censored at medication discontinuation of the assigned antipsychotic or at the end of the first phase, whichever came first.
Unadjusted and adjusted Cox regression models assessed the strength of associations between each baseline patient characteristic and hazard of first hospital admission. In the adjusted models, each variable of interest was first forced into each model and all baseline covariates were then stepped in with specified entry (p<.15) and retention (p<.05) criteria. Results are presented as hazards ratios with associated 95% confidence intervals (CI) and p values. A sensitivity analysis compared stratified rates of all schizophrenia-related hospitalizations per year of medication exposure as the outcome instead of first hospital admission.
A Poisson regression analysis was used for the sensitivity analysis in which annual hospitalization risk was the dependent variable. Kaplan-Meier curves for each antipsychotic medication group were generated to estimate the survival function to first hospital admission. The log-rank test was used to compare the five medication groups.
Results
During the first phase of the study, 203 of the 1,460 patients (14%) were admitted as inpatients on one or more occasions (Table 1). The overall frequency of first hospital admission was 6.4 per 10,000 days of follow-up.
Sociodemographic characteristics
In unadjusted models, the hazard of first psychiatric hospital admission was not significantly related to patients' age, sex, educational achievement, employment status, or living status. Compared with white race or ethnicity, African-American ancestry was significantly related to hospital admission in the unadjusted models, but the relationship did not remain statistically significant after adjustment for potentially confounding covariates. Being married was significantly related to a lower hazard of admission in the unadjusted but not the adjusted analysis (Table 1).
Background clinical characteristics
Psychiatric hospital admission in the past year emerged as the most powerful predictor of hospital admission. First antipsychotic treatment at age 17 or younger was also strongly and independently related to hazard of hospital admission. Major depressive disorder and anxiety disorders occurring during the past five years were not significantly related to hospital admission, but occurrence of alcohol and drug use disorders during this period significantly predicted risk of hospitalization in unadjusted and adjusted models (Table 2).
Baseline clinical and treatment characteristics
The hazard of hospital admission was significantly increased for patients who received severe baseline CGI ratings compared with those who received mild CGI ratings and for patients who received high scores on the total, positive, and psychopathology subscales of the PANSS compared with those who received low scores. Similar differences were not observed for scores on the PANSS negative-symptom subscale, and differences in the PANSS psychopathology score did not remain significant after statistical adjustment (Table 3). In relation to results for olanzapine, the hazard of hospital admission was increased for each of the other antipsychotic medications, although the comparison with risperidone was not significant after adjustment for potentially confounding covariates (Table 3). In relation to risperidone, quetiapine was associated with a significantly greater hazard of hospital admission (adjusted hazard ratio [AHR]=1.50, 95% CI=1.01–2.22 and hazard ratio [HR]=1.49, CI=1.01–2.20). Ziprasidone was associated with greater hazard of admission than risperidone (AHR=1.89, CI=1.19–3.01), but the relationship did not remain significant after statistical adjustment (HR=1.52, CI=.96–2.41) (data not shown).
The results were little changed by extension of the risk period to 14 days beyond medication discontinuation (data not shown). With olanzapine as the reference group, risperidone was associated with an AHR of 1.48 (CI=.96–2.28); perphenazine, 1.69 (CI=1.06–2.70); ziprasidone, 2.54 (CI=1.57–4.09); and quetiapine, 2.06 (CI=1.36–3.12). Analysis of stratified rates of all schizophrenia-related hospital admissions per year of medication exposure revealed AHRs of .14 for olanzapine (CI=.09–.19), .26 for risperidone (CI=.18–.34), .28 for perphenazine (CI=.18–.38), .36 for ziprasidone (CI=.22–.50), and .38 for quetiapine (CI=.28–.48).
The log-rank test of equality over strata was highly significant (χ2=19.72, df=4, p=.006). Pairwise comparisons of the curves with olanzapine were significant for quetiapine (p<.001) and ziprasidone (p<.001) but not for perphenazine (p=.05) or risperidone (p=.16). Table 4 presents mean and median time to first hospital admission by initial antipsychotic medication assignment.
Patients with low social function, as measured by the Quality of Life Scale, also had a significantly greater likelihood of hospital admission than those with high social function. Baseline measures of attitudes toward antipsychotic medications, awareness of illness, and quality of life related to physical health at baseline and a lifetime history of having injured another person were not significantly related to risk of hospital admission (Table 5).
Discussion
Outpatients with schizophrenia varied in their risk of hospital admission. During the first phase of the CATIE trial, a recent psychiatric hospital admission, comorbid drug or alcohol use disorder, and severity of positive symptoms at study entry each predicted inpatient psychiatric admission. Similar patterns have been observed among other schizophrenia patient populations (5,6,25). Interventions that successfully reduce use of alcohol and drugs and stabilize symptoms are likely to lower risk of hospital admission among individuals with schizophrenia.
Comorbid alcohol and drug use disorders increased risk of hospital admission to a roughly comparable degree. Comparing bivariate and multivariate regressions further suggests that this risk was largely independent of the effects of baseline symptom severity and global function. Substance use may trigger relapse and hospital admission through the psychoactive effects of the substances themselves (26) or through their tendency to increase antipsychotic medication nonadherence.
Potential adverse effects of comorbid substance use disorders extend beyond risk of relapse and hospital admission to increased risk of violence, incarceration, and homelessness (27,28). Yet despite the high co-occurrence of schizophrenia and substance use disorders, widespread problems persist in the quality of care for patients with both disorders (29). Providing integrated treatment for this patient population should be a top priority for policy and service system planning (30).
Low social function at study entry also predicted hospital admission. Previous CATIE analyses (31) and other research (32) reveal that social function in schizophrenia is correlated with severity of positive and negative symptoms. Yet comparing the bivariate and multivariate analyses suggests that low social function predicted hospital admission largely independently of baseline positive and negative symptoms. Deficits in social function may increase hospital admission risk by interfering with recruitment of social support or help-seeking behavior during periods of distress (33). Psychosocial treatments that target social function, such as social skills training, might lower inpatient admission risk by improving function in these areas. In one small clinical trial of social skills training (N=48 in both the experimental and control groups), there was a trend toward lower rates of hospital admission among the experimental group (34). In general, however, social skills training tends to have smaller, though significant, beneficial effects on distal outcomes, such as relapse, than on proximal outcomes, such as interpersonal living skills and psychosocial function (35).
Early age of first antipsychotic medication was associated with a greater hazard of psychiatric hospital admission. Schizophrenia starting during childhood or early adolescence tends to be severe and follow a poor long-term course (36). An association between age of first antipsychotic use and hospital admission risk provides additional evidence for the value of age of onset of disorder for predicting the long-term course of schizophrenia. Tardive dyskinesia also conferred an increased risk of hospital admission, an observation that extended earlier findings indicating that tardive dyskinesia is related to elevated positive symptoms (37). An association between tardive dyskinesia and hospital admission is also consistent with the concept that tardive dyskinesia increases vulnerability to exacerbations of psychotic symptoms (38).
In keeping with a previous CATIE report (13), we found significant differences among antipsychotic medications in time to first inpatient admission. This variability is presumably mediated by differences in the neuroreceptor-binding profiles of the five study drugs. According to one meta-analysis, olanzapine and risperidone, but not quetiapine and ziprasidone, have greater overall efficacy for schizophrenia symptoms than first-generation medications (39). These differences in overall symptom efficacy among medications are consistent with the risk of hospital admission associated with their use found in this study. These results support the concept that appropriate antipsychotic medication tends to reduce hospital admission through improved symptom control.
Clinical selection of antipsychotic medications should take into consideration not only symptom control but also variation in metabolic effects and other adverse outcomes associated with the different medications. In the CATIE study, clinically significant weight gain was most common among patients assigned to olanzapine followed in descending order by quetiapine, risperidone, perphenazine, and ziprasidone (13).
Severity of negative symptoms at baseline was not a significant predictor of hospital admission. By contrast, an earlier cross-sectional study of psychotic patients reported that inpatients were more likely than outpatients to have negative symptoms (11). It is not possible to determine on the basis of this study the extent to which negative symptoms among inpatients are a consequence of rather than a risk factor for inpatient treatment. Understimulation of a hospital environment, excessive use of sedating medications in some inpatient settings, and dysphoria related to institutional restrictions may contribute to the expression of negative symptoms among inpatients.
Although negative symptom severity did not predict hospital admission, it is an important predictor of poor long-term outcome among individuals with schizophrenia (40). According to one large prospective study, social amotivation was correlated with shorter time to rescue from an experimental, low-dose antipsychotic regimen with supplementary antipsychotic medication (41).
Poor insight into a need for treatment, which is common among those with schizophrenia (42), was not a predictor of hospital admission risk. This finding contrasts with previous reports associating low insight with increased risk of inpatient admission (43,44). The connection between poor insight and risk of hospital admission is presumably mediated by decreased medication nonadherence (45). Because the first phase of the CATIE study did not include time following medication discontinuation, the effects of low insight on risk of hospital admission may have been substantially attenuated. This study design feature may also help to explain why unfavorable attitudes toward antipsychotic medication did not predict hospital admission.
This study had several important limitations. First, its design, as mentioned, did not permit assessment of the effects of medication nonadherence, a powerful risk factor for hospital admission (4). Second, because the analysis was limited to hospital admissions that are related to schizophrenia symptoms, it did not capture other admissions to psychiatric hospitals that were not directly driven by schizophrenia symptoms. Third, because hospital admissions were assessed by clinician report, admissions of which the clinician was unaware were not captured. Fourth, because CATIE systematically excluded persons experiencing a first schizophrenia episode, pregnant or breast-feeding women, and adults with serious and unstable medical conditions, the results cannot be safely extended to these populations. Fifth, the relatively small samples of some strata acted to constrain the power to detect significant group differences. Nonetheless, these limitations exist in the context of a large, well-characterized, and prospectively assessed cohort of adults with schizophrenia.
Conclusions
Several specific patient characteristics, especially early onset of disease, hospital admission in the past year, comorbid substance use disorder, global illness severity, and poor social function, were found to contribute to risk of hospital admission. These factors should help guide clinical and programmatic efforts to focus outpatient care on schizophrenia patients at high risk for hospital admission. Nevertheless, there is also a need to assess the role of relevant community services, the quality and continuity of outpatient care, and family and social support in reducing the risk of hospital admission (46).
Acknowledgments and disclosures
This project was supported by a research grant from Eli Lilly and Company to Columbia University, for which Dr. Olfson is principal investigator. In addition, Dr. Olfson has received a research grant to Columbia University from Bristol-Myers Squibb, and Dr. Marcus has served as a consultant to Bristol-Myers Squibb.
The authors report no competing interests.
References
1.
Carr VJ, Neil AL, Halpin SA, et al.: Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Australia and New Zealand Journal of Psychiatry 37:31–40, 2003
2.
Hendryx MS, Russo JE, Stegner B, et al.: Predicting rehospitalization and outpatient services from administration and clinical databases. Journal of Behavioral and Health Services Research 30:342–351, 2003
3.
Owens P, Myers M, Elixhauser A: Care of Adults With Mental Health and Substance Abuse Disorders in U.S. Community Hospitals, 2004. Rockville, Md, US Department of Health and Human Services, Agency for Healthcare Research and Quality, 2007
4.
Valenstein M, Ganoczy D, McCarthy JF, et al.: Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. Journal of Clinical Psychiatry 67:1542–1550, 2006
5.
Olfson M, Mechanic D, Boyer C, et al.: Assessing clinical predictions of early rehospitalization in schizophrenia. Journal of Nervous and Mental Disease 187:721–729, 1999
6.
Doering S, Mutter E, Kopcke W, et al.: Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophrenia Bulletin 24:87–98, 1998
7.
Werneck AP, Elkis H: Predictors of rehospitalization in three years of treatment after hospital discharge. Schizophrenia Research 102:270–279, 2008
8.
Angermeyer MC, Kuhn L, Goldstein JM: Gender and the course of schizophrenia: differences in treated outcome. Schizophrenia Bulletin 16:293–307, 1990
9.
Goldstein JM: Gender differences in the course of schizophrenia. American Journal of Psychiatry 145:684–689, 1988
10.
Chabungbam G, Avasthi A, Sharan P: Sociodemographic and clinical factors associated with relapse in schizophrenia. Psychiatric and Clinical Neuroscience 61:587–593, 2007
11.
Morgan V, Korten A, Jablensky A: Modifiable risk factors for hospitalization among people with psychosis: evidence from the National Study of Low Prevalence (Psychotic) Disorders. Australia and New Zealand Journal of Psychiatry 40:683–690, 2006
12.
Sullivan G, Wells KB, Morgenstern H, et al.: Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. American Journal of Psychiatry 152:1749–1756, 1995
13.
Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209–1223, 2005
14.
First MB, Spitzer RL, Williams JBW, et al.: Structured Clinical Interview for DSM-IV (SCID-I), User's Guide and Interview Research Version. New York, New York Psychiatric Institute, Biometrics Research Department, 1995
15.
Steadman HJ, Mulvey EP, Monahan J, et al.: Violence by people discharged from acute inpatient psychiatric facilities and others in the same neighborhoods. Archives of General Psychiatry 55:383–401, 1998
16.
Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. Pub no 76-338. Rockville, Md, US Department of Health, Education, and Welfare, Alcohol, Drug Abuse, and Mental Health Administration, 1976
17.
Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 39:486–487, 1982
18.
Kay SR, Opler LA, Lindenmayer JP: The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. British Journal of Psychiatry Supplement:59–67, 1989
19.
Addington D, Addington J, Schissel BA: A depression rating scale for schizophrenics. Schizophrenia Research 3:247–251, 1990
20.
Heinrichs DW, Hanlon TE, Carpenter WT: The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10:388–396, 1984
21.
Hogan TP, Awad AF, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 22:347–352, 1992
22.
McEvoy JP, Apperson LJ, Appelbaum PS, et al.: Insight in schizophrenia: its relationship to acute psychopathology. Journal of Nervous and Mental Disease 177:43–47, 1989
23.
Ware J, Kosinski M, Keller SD: A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Medical Care 34:220–233, 1996
24.
Faries DE, Nyhuis AW, Ascher-Svanum H: Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example. Cost Effectiveness and Resource Allocation 7:11–0, 2009. Available at
25.
Bartels SJ, Teague GB, Drake RE, et al.: Substance abuse in schizophrenia: service utilization and costs. Journal of Nervous and Mental Disease 181:227–232, 1993
26.
Lieberman JA, Kinon BJ, Loebel AD: Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophrenia Bulletin 16:97–110, 1990
27.
Fazel S, Langstrom N, Hjern A, et al.: Schizophrenia, substance abuse, and violent crime. JAMA 301:2016–2023, 2009
28.
Nordentoft M, Knudsen HC, Jessen-Petersen B, et al.: Copenhagen Community Psychiatric Project (CCPP): characteristics and treatment of homeless patients in the psychiatric services after introduction of community mental health centres. Social Psychiatry and Psychiatric Epidemiology 32:369–378, 1997
29.
Busch AB, Lehman AF, Goldman H, et al.: Changes over time and disparities in schizophrenia treatment quality. Medical Care 47:199–220, 2009
30.
Dixon LB, Dickerson F, Bellack AS, et al.: The 2009 PORT psychosocial treatment recommendations and summary statements. Schizophrenia Bulletin 36:48–70, 2010
31.
Mohamed S, Rosenheck R, Swartz M, et al.: Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry 165:978–987, 2008
32.
Perlick DA, Rosenheck RA, Kaczynski R, et al.: Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. Schizophrenia Reseach 99:192–199, 2008
33.
Nuechterlein K, Dawson ME: A heuristic vulnerability-stress model of schizophrenia. Schizophrenia Bulletin 10:300–312, 1984
34.
Xiang Y, Weng Y, Li W, et al.: Training patients with schizophrenia with the community reentry module: a controlled study. Social Psychiatry and Psychiatric Epidemiology 41:464–469, 2006
35.
Kurtz MM, Mueser KT: A meta-analysis of controlled research on social skills training for schizophrenia. Journal of Consulting and Clinical Psychology 76:491–504, 2008
36.
Rabinowitz J, Levine SZ, Häfner H: A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophrenia Research 88:96–101, 2006
37.
Miller DD, McEvoy JP, Davis SM, et al.: Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research 80:33–43, 2005
38.
Lieberman JA, Kane JM, Sarantakos S, et al.: Prediction of relapse in schizophrenia. Archives of General Psychiatry 44:597–603, 1987
39.
Leucht S, Arbter D, Li C, et al.: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41, 2009
40.
Milev P, Ho BC, Arndt S, et al.: Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first episode study with 7 year follow-up. American Journal of Psychiatry 162:495–506, 2005
41.
Sayers SL, Curran PJ, Mueser KT: Factor structure and construct validity of the Scale for the Assessment of Negative Symptoms. Psychological Assessment 8:269–280, 1996
42.
Dam J: Insight in schizophrenia: a review. Nordic Journal of Psychiatry 60:114–120, 2006
43.
Drake RJ, Dunn G, Tarrier N, et al.: Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. Journal of Clinical Psychiatry 68:81–86, 2007
44.
Yen C-F, Yeh M-L, Chen C-S, et al.: Predictive value of insight for suicide, violence, hospitalization, and social adjustment for outpatients with schizophrenia: a prospective study. Comprehensive Psychiatry 43:443–447, 2002
45.
Lincoln TM, Lullmann E, Rief W: Correlates and long-term consequences of poor insight in patients with schizophrenia: a systematic review. Schizophrenia Bulletin 33:1324–1342, 2007
46.
Fortney JC, Xu S, Dong F: Community-level correlates of hospitalizations for persons with schizophrenia. Psychiatric Services 60:772–778, 2009
Figures and Tables
Information & Authors
Information
Published In
Cover: Carmel, by John O'Shea, circa 1927. Oil on canvas, 28 × 32¼
inches. Crocker Art Museum, Melza and Ted Barr Collection. 2008.107.
History
Published online: 1 October 2011
Published in print: October 2011
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).